Impact of the microbiome on cancer progression and response to anti-cancer therapies

Adv Cancer Res. 2019:143:255-294. doi: 10.1016/bs.acr.2019.03.005. Epub 2019 Apr 17.

Abstract

Humans are a colonized with trillions of commensal microorganisms which exert a profound effect on normal host physiology and immune function through an abundance of genetic and metabolic by-products. Although the commensal microbiome has beneficial functions to host physiology, perturbations of the composition of the commensal microbiome or the homeostatic mucosal environment can lead to the induction of immune pathology and systemic inflammation. In the context of cancer progression or response to immune therapy, this inflammation can be detrimental, resulting in tumor growth and the promotion of immune suppression. On the other hand, significant associations have been identified whereby certain commensal microorganisms are able to enhance T cell function or are required for tumor control in cancer patients treated with certain immune therapies and chemotherapies. The focus of this chapter is to highlight the role of the commensal microbiome during tumor progression and in response to immune therapies.

Keywords: Cancer; Commensal dysbiosis; Immunosuppression; Immunotherapy; Microbiome.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Homeostasis
  • Humans
  • Immune System / immunology*
  • Immunomodulation
  • Immunotherapy / methods*
  • Inflammation / immunology*
  • Microbiota / immunology*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / microbiology
  • Symbiosis
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / microbiology

Substances

  • Antineoplastic Agents